Loading...
•
Dec 31, 2024
Eli Lilly Q4 2024 Earnings Report
Key Takeaways
Lilly reported strong Q4 2024 results with a 45% increase in revenue to $13.53 billion, driven by volume growth from Mounjaro and Zepbound. EPS surged 102% to $4.88, while non-GAAP EPS increased 114% to $5.32. Net income more than doubled year-over-year.
Revenue by Segment
Forward Guidance
Lilly expects continued strong revenue growth in 2025, driven by new product launches and expanded manufacturing capacity.
Positive Outlook
- Projected revenue growth to $58B-$61B in 2025
- Expected EPS range of $22.05-$23.55 on a reported basis
- Continued strong demand for Mounjaro and Zepbound
- Significant investment in manufacturing expansion
- Potential new product launches in 2025
Challenges Ahead
- Higher interest expenses expected in 2025
- Tax rate expected to rise to 16%
- Continued pricing pressures on key drugs
- Increased competition in the obesity and diabetes market
- Dependency on regulatory approvals for pipeline success
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...